Garson J A, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L
Department of Medical Microbiology, University College and Middlesex School of Medicine, London, U.K.
J Med Virol. 1992 Jul;37(3):210-4. doi: 10.1002/jmv.1890370311.
A quantitative polymerase chain reaction (PCR) assay for hepatitis C viral RNA (HCV-RNA) was used to monitor viraemia levels in six patients at multiple time points before, during, and after interferon therapy for chronic non-A, non-B hepatitis (NANBH). Prior to therapy, serum HCV-RNA was detected in all patients at approximately 10(4)-10(5) HCV genomes/ml. HCV viraemia became undetectable within 1 month of commencing interferon in three of the five patients whose alanine aminotransferase (ALT) levels decreased to normal on therapy. In the remaining two responder patients, viraemia levels declined more slowly, becoming undetectable after a period of several months. Recurrence of viraemia during therapy was observed in two cases. The one patient whose serum ALT levels remained elevated throughout therapy showed no decline in viraemia. On stopping interferon after a 6 months course, HCV genome titres climbed rapidly in all patients, reaching higher levels than had been observed prior to therapy. Biochemical relapse occurred within 7 months of ending interferon treatment in all but one of the patients who demonstrated this viraemia "rebound" phenomenon.
采用丙型肝炎病毒RNA（HCV-RNA）定量聚合酶链反应（PCR）检测法，在6例慢性非甲非乙型肝炎（NANBH）患者接受干扰素治疗的前、中、后多个时间点监测病毒血症水平。治疗前，所有患者血清中均可检测到HCV-RNA，浓度约为10⁴-10⁵ HCV基因组/ml。在接受治疗时丙氨酸转氨酶（ALT）水平降至正常的5例患者中，有3例在开始使用干扰素后1个月内病毒血症检测不到。其余2例有反应的患者，病毒血症水平下降较慢，数月后检测不到。治疗期间观察到2例病毒血症复发。在整个治疗过程中血清ALT水平持续升高的1例患者，病毒血症未见下降。在为期6个月的疗程结束后停用干扰素，所有患者的HCV基因组滴度迅速攀升，达到高于治疗前观察到的水平。除1例出现这种病毒血症“反弹”现象的患者外，所有患者在停止干扰素治疗后7个月内均发生生化复发。
